CTOs on the Move

Enveric Biosciences

www.enveric.com

 
Enveric Biosciences is a patient-centric biotechnology company endeavoring to enhance the lives of those who are adversely affected by the side effects of cancer treatments. Enveric Biosciences has set out with the goal of rigorously testing natural compounds, starting with cannabinoids, to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.enveric.com
  • 4851 Tamiami Trail N Suite 200
    Naples, FL USA 34103
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Enveric Biosciences raised $10M on 01/12/2021
Enveric Biosciences raised $12.8M on 02/09/2021

Similar Companies

Anji Pharmaceuticals

Anji Pharma is a global pharmaceutical company focused on tackling high-value targets validated by human genetics. We are exhaustive in our discovery and clinical efforts while nimble in our strategy and execution. We have assembled a world-class team of scientist entrepreneurs who are committed to accelerate innovative medicines in China and worldwide.

CSI TESTING

CSI TESTING Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Affordable RX

Affordable RX is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Wellinks

Wellinks is a virtual COPD management solution empowering members to live fully, and breathe freely.

Lundbeck

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company`s products are targeted at disease areas such as depression, schizophrenia, Parkinson`s disease and Alzheimer`s disease. According to the World Health Organization, WHO, more than 700 million cases of psychiatric and neurological disorders are reported every year. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives. As these diseases also involve major socio-economic costs, it is imperative for the general society that new and innovative pharmaceuticals are developed. Over the past 50 years, new pharmaceuticals have revolutionised the treatment options, but there remains a large unmet need for new and innovative therapeutics. Focus on R&D is the most important pillar in Lundbeck`s ambition to improve treatment for people living with psychiatric and neurological disorders. We are specialists in our area and have research facilities in Denmark and China, and more than 1,000 employees work in our R&D units. We cooperate closely with strategic partners all over the world, ensuring the best possible foundation for innovation and the development of new treatment solutions. Lundbeck employs approximately 5,300 people worldwide, 1,700 of whom are based in Denmark. We have employees in 55 countries, and our products are registered in more than 100 countries. We have production facilities in China, Denmark, France and Italy and research centres in Denmark and China.